These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 6297858)

  • 1. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.
    Polak A; Scholer HJ; Wall M
    Chemotherapy; 1982; 28(6):461-79. PubMed ID: 6297858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.
    Polak A
    Chemotherapy; 1987; 33(5):381-95. PubMed ID: 2822362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
    Van Cutsem J
    Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimycotic activity of BAY N 7133 in animal experiments.
    Plempel M
    J Antimicrob Chemother; 1984 May; 13(5):447-63. PubMed ID: 6330018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole.
    Graybill JR; Williams DM; Van Cutsem E; Drutz DJ
    Rev Infect Dis; 1980; 2(4):551-58. PubMed ID: 6255531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
    Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Krupa D; Pikounis VB; Kropp H; Bartizal K
    Antimicrob Agents Chemother; 1995 May; 39(5):1077-81. PubMed ID: 7625792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oral flucytosine and ketoconazole as therapy for experimental cryptococcal meningitis.
    Craven PC; Graybill JR
    J Infect Dis; 1984 Apr; 149(4):584-90. PubMed ID: 6327836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
    Hamilton JD; Elliott DM
    J Infect Dis; 1975 Feb; 131(2):129-37. PubMed ID: 1090685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
    Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In-vitro and in-vivo activity of itraconazole].
    Van Cutsem J
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
    Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Pikounis VB; Balkovec JM; Bouffard AF; Dropinski JF; Rosen H; Kropp H; Bartizal K
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2333-8. PubMed ID: 9371329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
    Mitsuyama J; Nomura N; Hashimoto K; Yamada E; Nishikawa H; Kaeriyama M; Kimura A; Todo Y; Narita H
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1318-24. PubMed ID: 18227186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole.
    Perfect JR; Durack DT
    J Infect Dis; 1982 Sep; 146(3):429-35. PubMed ID: 6286799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifungal combination therapy in invasive fungal infections].
    Gellen-Dautremer J; Lanternier F; Dannaoui E; Lortholary O
    Rev Med Interne; 2010 Jan; 31(1):72-81. PubMed ID: 19767130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.
    Hector RF; Yee E
    Antimicrob Agents Chemother; 1990 Mar; 34(3):448-54. PubMed ID: 2159257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
    Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
    J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo studies on synergistic antifungal activity.
    Shadomy S
    Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo models: evaluating antifungal agents.
    Dixon DM
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):729-38. PubMed ID: 3448452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in systemic mycosis.
    Polak A
    J Chemother; 1990 Aug; 2(4):211-7. PubMed ID: 2230904
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of systemic mycoses in immunodeficiency].
    Just-Nübling G; Stille W
    Immun Infekt; 1991 Aug; 19(4):116-20. PubMed ID: 1937558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.